| 标题： | 中西医结合治疗和预防COVID-19动态循证指南 |
| title： | IntegratingChineseandWesternMedicineforthePreventionandTreatmentof COVID-19:ALivingEvidence-basedClinicalPracticeGuideline |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 中医药指南 |
| classification： | Traditional Chinese Medicine guideline |
| 领域： | 治疗 |
| field： | Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 本指南可适用于发热门诊、急诊科、重症医学科、呼吸科、中西医结合等诊治COVID-19感染肺炎患者的医务人员、公共卫生人员、科研工作者及社区居民。 |
| Guide users： | This guide can be applied to medical staff, public health staff, scientific research workers and community residents who diagnose and treat patients with COVID-19 pneumonia in fever clinics, emergency departments, intensive care departments, respiratory departments, integrated Chinese and Western medicine. |
| 证据分级方法： | Based on the quality of evidence evaluated by the GRADE evaluation system and develops evidence summary table (including "Evidence Profile" and "Evidence to Decision (EtD) table"). When new evidence appears, the guideline evidence review group will update the above two tables in a timely manner, then form a living summary table to confirm new recommendations. |
| Evidence grading method： | |
| 制定单位： | 兰州大学 |
| Formulating unit： | Lanzhou University |
| 注册时间： | 2020-10-29 |
| Registration time： | |
| 注册编号： | IPGRP-2020CN164 |
| Registration number： | |
| 指南制订的目的： | 自新型冠状病毒（COVID-19）引起的肺炎疫情发生以来，全球感染人数不断增长，2020年8月1日，世卫组织发布声明称：新冠疫情将继续成为“国际关注的突发公共卫生事件”。当前仍无特效药治疗新冠肺炎，疫苗研发也处于临床试验阶段，中医药在新冠肺炎治疗中充分彰显其特色和优势，并可在全程发挥作用。目前已发表的中医药/中西医结合治疗COVID-19指南中，由于制订时间较早，缺乏直接临床证据等因素，推荐意见多基于国家或各省颁布的诊疗方案，或以SARS、MARS等其他呼吸系统疾病相关研究作为间接证据，极少数推荐意见基于新冠临床试验的直接证据。动态指南（living guidelines）则是通过证据监测系统，不断检索推荐意见相关的新证据，将其纳入证据摘要，并在证据发生实质性变化时迅速更新指南建议，以创建一个实时的、不断更新的证据系统。动态系统评价和动态指南的发展可及时有效地促进最佳研究证据用于临床实践。因此，本动态指南基于动态系统评价：the Treatment for Traditional Chinese Medicine of COVID-19: A Living Systematic Review and Meta-Analysis制订中西医结合治疗和预防COVID-19的动态指南。 |
| Purpose of the guideline： | Since the outbreak of pneumonia caused by the novel coronavirus (COVID-19), the number of people infected worldwide has been increasing. On August 1, 2020, the WHO issued a statement stating that the COVID-19 will continue to be a “public health emergency of international concern”. At present, there is still no specific medicine to treat COVID-19, and Vaccine development is also in clinical trials stage. Traditional Chinese medicine has fully demonstrated its characteristics and advantages in the treatment of COVID-19 , and can play a role throughout the process. In the currently published guidelines for the treatment of COVID-19 with traditional Chinese medicine/integrated traditional Chinese and Western medicine, due to factors such as early formulation and lack of direct clinical evidence, the recommendations are mostly based on the diagnosis and treatment plans issued by the country or provinces, or based on SARS, MARS and other respiratory diseases. Systematic disease-related studies are used as indirect evidence, and very few recommendations are based on direct evidence from clinical trials of the COVID-19. Living guidelines use the evidence monitoring system to continuously search for new evidence related to recommendations, incorporate them into the evidence summary, and quickly update the guidelines and recommendations when the evidence changes substantially, so as to create a real-time and continuously updated Evidence system. The development of dynamic systematic reviews and dynamic guidelines can promptly and effectively promote the best research evidence for clinical practice. Therefore, this living guideline is based on a living systematic review: the Treatment for Traditional Chinese Medicine of COVID-19: A Living Systematic Review and Meta-Analysis to develop a living guideline for the treatment and prevention of COVID-19 with integrated traditional Chinese and Western medicine. |
